Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aerie Pharmaceuticals (AERI)

Aerie Pharmaceuticals (AERI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 753,609
  • Shares Outstanding, K 49,417
  • Annual Sales, $ 194,130 K
  • Annual Income, $ -74,810 K
  • 60-Month Beta -0.06
  • Price/Sales 3.88
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade AERI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.16
  • Most Recent Earnings -0.27 on 11/03/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 1.81%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.51
  • Number of Estimates 2
  • High Estimate -0.42
  • Low Estimate -0.60
  • Prior Year 1.09
  • Growth Rate Est. (year over year) -146.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.17 +0.53%
on 10/24/22
15.25 unch
on 11/18/22
+0.07 (+0.46%)
since 10/18/22
3-Month
10.78 +41.47%
on 08/22/22
15.37 -0.78%
on 09/07/22
+3.78 (+32.96%)
since 08/18/22
52-Week
4.81 +217.05%
on 06/02/22
15.37 -0.78%
on 09/07/22
+4.98 (+48.49%)
since 11/18/21

Most Recent Stories

More News
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”)....

ALC : 68.32 (+0.49%)
AERI : 15.25 (+0.07%)
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up

ImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates. The company raises its financial guidance for 2022

NVS : 87.71 (+0.48%)
LLY : 365.25 (+0.98%)
IMGN : 5.15 (-0.19%)
AERI : 15.25 (+0.07%)
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates

Aerie (AERI) delivered earnings and revenue surprises of 35.71% and 2.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AERI : 15.25 (+0.07%)
SAGE : 37.79 (+0.91%)
Aerie: Q3 Earnings Snapshot

Aerie: Q3 Earnings Snapshot

AERI : 15.25 (+0.07%)
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results...

AERI : 15.25 (+0.07%)
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance

Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.

NBIX : 122.15 (+2.67%)
ZTS : 150.10 (-0.25%)
AERI : 15.25 (+0.07%)
ASRT : 2.95 (+1.37%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBTX, POSH, PBFX, RNWK, AERI

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SBTX : 5.87 (+1.03%)
POSH : 17.80 (+0.06%)
PBFX : 21.55 (-1.19%)
RNWK : 0.7158 (-0.45%)
AERI : 15.25 (+0.07%)
The Zacks Analyst Blog Highlights SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals

SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals are part of The Zacks top Analyst Blog.

RELL : 26.55 (+8.54%)
AERI : 15.25 (+0.07%)
SBOW : 35.69 (+0.39%)
PHX : 3.70 (+2.21%)
AMAL : 26.44 (+4.22%)
Talaris (TALS) Down on Patient Death From Renal Transplant Study

Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.

CPRX : 16.97 (-0.35%)
AERI : 15.25 (+0.07%)
ACER : 1.1918 (+1.86%)
TALS : 1.4700 (+2.80%)
Add These 4 Top-Ranked Liquid Stocks For Healthy Gains

Here are four top-ranked liquid stocks, Oxford Industries (OXM), Aerie Pharmaceuticals (AERI), Perion Network (PERI), and Pure Storage (PSTG), which investors can add to their portfolio for returns.

OXM : 112.99 (-1.44%)
PERI : 27.28 (+3.73%)
AERI : 15.25 (+0.07%)
PSTG : 30.46 (-0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Aerie Pharmaceuticals is a commercial-stage company focused on the development and commercialization of eye disease therapies including glaucoma and other eye-diseases.'In 2017, Aerie received FDA approval for its lead drug, Rhopressa, for the lowering of elevated intraocular pressure (IOP) in patients...

See More

Key Turning Points

3rd Resistance Point 15.26
2nd Resistance Point 15.26
1st Resistance Point 15.25
Last Price 15.25
1st Support Level 15.24
2nd Support Level 15.24
3rd Support Level 15.23

See More

52-Week High 15.37
Last Price 15.25
Fibonacci 61.8% 11.34
Fibonacci 50% 10.09
Fibonacci 38.2% 8.84
52-Week Low 4.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar